Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-09T19:57:03.108Z Has data issue: false hasContentIssue false

39 - Dantrolene

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Dantrium, Dantamacrin, Dantrolen, Revonto, Ryanodex

Generic?

• Yes

Class

• Muscle relaxant

Commonly Prescribed for

(FDA approved in bold)

Chronic spasticity

Malignant hyperthermia (MT)

• Exercise-induced muscle pain

• Heat stroke

• Neuroleptic malignant syndrome

How the Drug Works

• Dantrolene produces relaxation by directly interfering with the release of calcium from the sarcoplasmic reticulum, and weakening muscle contraction. It blocks RYR1 receptors, which show prolonged open state during malignant hyperthermia

How Long Until It Works

• MT: immediate

• Pain: hours to days

If It Works

• Discontinue use once MT symptoms remit. For chronic spasticity, continue to use with standard precautions

If It Doesn't Work

• For spasticity, increase to highest tolerated dose. If ineffective, stop after 45 days and consider alternative treatments. In MT cases, stop all anesthetics

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For focal spasticity, i.e., post-stroke spasticity, botulinum toxin is often more effective and is better tolerated

• Use other centrally acting muscle relaxants with caution due to potential synergistic CNS depressant effect

• 100% oxygen, cold gastric lavage, cooling blankets, and cold IV fluids may be useful in MT

Tests

• Obtain baseline liver function studies then do periodically

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Some are related to CNS depression, others hepatic disease

Notable AEs

• Fatigue, diarrhea, drowsiness, weakness, respiratory failure, rash, labile blood pressure, confusion/depression, abdominal cramps, crystalluria, chills, and fever. Thrombophlebitis (highly irritating to peripheral veins) and extravasation tissue necrosis

Life-Threatening or Dangerous AEs

• Hepatotoxicity is not rare even after only short-term use, especially in patients that are females, over 35, taking multiple medications, or taking dose greater than 800 mg

• Less common: heart failure, pulmonary edema, and hematological abnormalities have been reported

Weight Gain

• Unusual

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 143 - 145
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Dantrolene
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.040
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Dantrolene
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.040
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Dantrolene
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.040
Available formats
×